SIT Pharma acquires DINTOINA
SIT Pharma is pleased to announce the acquisition of DINTOINA brand.
The product is indicated for generalized epilepsy control, excluding petit mal and partial seizures.
Day: 2 April 2025
sitpharma
sitpharma
SIT Pharma is pleased to announce the acquisition of DINTOINA brand.
The product is indicated for generalized epilepsy control, excluding petit mal and partial seizures.